# Acamprosate

## Alglutol 333mg delayed-release

| TAH Drug Code      | [OAGT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OAGT)                                                                                                                                                                                                               |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Alcohol dependence， Maintenance of abstinence.                                                                                                                                                                                                                                    |
| Dosing             | Alcoholism， maintenance of abstinence: 666 mg orally 3 times daily.                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                           |
| Contraindications  | Hypersensitivity to acamprosate calcium or any of its components. Severe renal impairment (CrCl of 30 mL/min or less). Hypercalcemia (avoided long-term using this drug in patients with hypercalcemia).                                                                           |
| Adverse Effects    | Common: Pruritus (4%)， Diarrhea (10-17%)， Flatulence (3%)， Nausea (4%)， Dizziness (3%)， Insomnia (7%)， Anxiety (6%)， Depression (5%) Serious: Cardiomyopathy， Deep thrombophlebitis， Heart failure， Mesenteric arterial occlusion， acute， Shock， Suicidal intent (1%) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest High Risk                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/acamprosate-drug-information)                                                                                                                                                                                                         |

